These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9540935)

  • 1. A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis.
    Vintzileos AM; Ananth CV; Smulian JC; Fisher AJ; Day-Salvatore D; Beazoglou T
    Obstet Gynecol; 1998 Apr; 91(4):529-34. PubMed ID: 9540935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA; Watson SE; Washington AE
    Obstet Gynecol; 1994 Dec; 84(6):903-12. PubMed ID: 7970468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of antenatal screening for cystic fibrosis.
    Cuckle HS; Richardson GA; Sheldon TA; Quirke P
    BMJ; 1995 Dec; 311(7018):1460-3; discussion 1463-4. PubMed ID: 8520332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs, effects, and savings of screening for cystic fibrosis gene carriers.
    Wildhagen MF; Hilderink HB; Verzijl JG; Verheij JB; Kooij L; Tijmstra T; ten Kate LP; Habbema JD
    J Epidemiol Community Health; 1998 Jul; 52(7):459-67. PubMed ID: 9799881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Informing policy for the Australian context - Costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis.
    Maxwell S; Brameld K; Youngs L; Geelhoed E; O'Leary P
    Aust N Z J Obstet Gynaecol; 2010 Feb; 50(1):51-9. PubMed ID: 20218998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carrier screening for cystic fibrosis: costs and clinical outcomes.
    Asch DA; Hershey JC; Dekay ML; Pauly MV; Patton JP; Jedrziewski MK; Frei F; Giardine R; Kant JA; Mennuti MT
    Med Decis Making; 1998; 18(2):202-12. PubMed ID: 9566453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population.
    Ginsberg G; Blau H; Kerem E; Springer C; Kerem BS; Akstein E; Greenberg A; Kolumbos A; Abeliovich D; Gazit E
    Health Econ; 1994; 3(1):5-23. PubMed ID: 8167800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is cystic fibrosis carrier screening cost effective?
    Wei S; Quigg MH; Monaghan KG
    Community Genet; 2007; 10(2):103-9. PubMed ID: 17380060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program.
    Warren E; Anderson R; Proos AL; Burnett LB; Barlow-Stewart K; Hall J
    Genet Med; 2005 Sep; 7(7):484-94. PubMed ID: 16170240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of carrier screening for cystic fibrosis in Australia.
    Norman R; van Gool K; Hall J; Delatycki M; Massie J
    J Cyst Fibros; 2012 Jul; 11(4):281-7. PubMed ID: 22425241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preconception cystic fibrosis carrier screening: costs and consequences.
    Weijers-Poppelaars FA; Wildhagen MF; Henneman L; Cornel MC; Kate LP
    Genet Test; 2005; 9(2):158-66. PubMed ID: 15943557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal screening for cystic fibrosis carriers: an economic evaluation.
    Rowley PT; Loader S; Kaplan RM
    Am J Hum Genet; 1998 Oct; 63(4):1160-74. PubMed ID: 9758600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal cystic fibrosis screening in Mexican Americans: an economic analysis.
    Doyle NM; Gardner MO
    Am J Obstet Gynecol; 2003 Sep; 189(3):769-74. PubMed ID: 14526311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
    Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
    J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in implementing prenatal screening for cystic fibrosis: results of a working conference.
    Haddow JE; Bradley LA; Palomaki GE; Doherty RA
    J Med Screen; 1999; 6(2):60-6. PubMed ID: 10444721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of genotyping versus sequencing for prenatal cystic fibrosis carrier screening.
    Avram CM; Dyer AL; Shaffer BL; Caughey AB
    Prenat Diagn; 2021 Oct; 41(11):1449-1459. PubMed ID: 34346064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for cystic fibrosis and its evaluation.
    Wildhagen MF; ten Kate LP; Habbema JD
    Br Med Bull; 1998; 54(4):857-75. PubMed ID: 10367419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.
    van der Ploeg CP; van den Akker-van Marle ME; Vernooij-van Langen AM; Elvers LH; Gille JJ; Verkerk PH; Dankert-Roelse JE;
    J Cyst Fibros; 2015 Mar; 14(2):194-202. PubMed ID: 25213034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preconception screening of parents and carrier state of cystic fibrosis in the Netherlands: expenses and savings].
    Verheij JB; Hilderink HB; Verzijl JG; Wildhagen MF; Habbema JD; ten Kate LP
    Ned Tijdschr Geneeskd; 1998 Mar; 142(13):706-10. PubMed ID: 9623144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis.
    Massie J; Forbes R; Dusart D; Bankier A; Delatycki MB
    J Paediatr Child Health; 2007 Nov; 43(11):721-3. PubMed ID: 17924936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.